Skip to main content

#WHO accelerates efforts to support response to #Sudan {hemorrhagic fever} virus disease #outbreak in #Uganda

Brazzaville/Kampala – Following the confirmation of an outbreak of Sudan virus disease – which belongs to the same family as Ebola virus disease – in Uganda today, World Health Organization (WHO) is mobilizing efforts to support the national health authorities to swiftly contain and end the outbreak

WHO is deploying senior public health experts and mobilizing staff from the country office to support all the key outbreak response measures. In addition, the Organization has allocated US$ 1 million from its Contingency Fund for Emergencies to help accelerate early action, and is readying medical supplies, including personal protective equipment to deliver to Uganda from its Emergency Response Hub in Nairobi. 

While there are no licensed vaccines for the Sudan virus disease, WHO is coordinating with developers to deploy candidate vaccines as an addition to the other public health measures. The vaccines will be deployed once all administrative and regulatory approvals are obtained. 

So far one confirmed case – a nurse from Mulago National Referral Hospital in the capital Kampala – has been reported. No other health workers or patients have shown symptoms of the disease.  A total of 45 contacts, including health workers and family members of the confirmed case (deceased) have been identified and are currently under close monitoring. The identification of the case in a densely populated urban requires rapid and intense response. 

“We welcome the prompt declaration of this outbreak, and as a comprehensive response is being established, we are supporting the government and partners to scale up measures to quicky identify cases, isolate and provide care, curb the spread of the virus and protect the population,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “Uganda’s robust expertise in responding to public health emergencies will be crucial in ending this outbreak effectively.”

There have been eight previous outbreaks of the Sudan virus disease, with five occurring in Uganda and three in Sudan. Uganda last reported an outbreak of Sudan virus disease in 2022. 

“Banking on the existing expertise, we are accelerating all efforts, including expertise, resources and tools to save lives and bring the outbreak to a halt swiftly,” said Dr Kasonde Mwinga, WHO Representative in Uganda. 

Sudan virus disease is a severe, often fatal illness affecting humans and other primates that is due to Orthoebolavirus sudanense (Sudan virus), a viral species belonging to the same genus of the virus causing Ebola virus disease.  Case fatality rates of Sudan virus disease have varied from 41% to 100% in past outbreaks. There are no approved treatments or vaccines for Sudan virus. Early initiation of supportive treatment has been shown to significantly reduce deaths from Sudan virus disease. 

Source: World Health Organization, Regional Office for Africa, https://www.afro.who.int/countries/uganda/news/who-accelerates-efforts-support-response-sudan-virus-disease-outbreak-uganda

_____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

Stability of #influenza viruses in the #milk of #cows and #sheep

Abstract In late 2023, H5N1 high pathogenicity avian influenza (HPAIV) started circulating in dairy cattle in the USA . High viral titres were detected in milk from infected cows , raising concerns about onwards human infections . Although pasteurisation was shown to effectively inactivate influenza viruses in milk, unpasteurised milk still poses a risk of infection, both from occupational exposure in dairies and from the consumption of raw milk. We therefore assessed how long influenza viruses could remain infectious for in milk without heat inactivation. We examined the stability of a panel of influenza viruses in milk , including a contemporary H5N1 HPAIV and a variety of other influenza A and D viruses. We incubated viruses in cows' milk under laboratory conditions : at room temperature to simulate exposure in dairies and at 4°C to simulate exposure to refrigerated raw milk. Following an isolated report of H5N1 viral RNA being detected in milk from a sheep in the UK , we also c...

#Evidence of #Viremia in Dairy #Cows Naturally Infected with #Influenza A {#H5N1} Virus, #California, #USA

Abstract We confirmed influenza A virus (IAV) by PCR in serum from 18 cows on 3 affected dairy farms in California, USA . Our findings indicate the presence of viremia and might help explain IAV transmission dynamics and shedding patterns in cows. An understanding of those dynamics could enable development of IAV mitigation strategies. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/7/25-0134_article ____